Evaluating N-acetylcysteine as a Protective Agent Against Chemotherapy-induced Neuropathy in Breast Cancer
Oral NAC at a dose of 1200 mg per day did not significantly reduce the incidence or severity of taxane-induced neuropathy. These findings suggest that the oral bioavailability of NAC may be insufficient to exert a protective effect and that future studies should consider alternative dosing strategies or routes of administration. The need for further research to optimize NAC's chemoprotective role in CIPN remains evident.
Authors
- Abdolazim Sedighi Pashaki (ORCID: https://orcid.org/0000-0003-2210-5797)
- Hossein Ranjbar (ORCID: https://orcid.org/0000-0002-8755-3761)
- Ehsan Akbari Hamed
- Kamran Sheikhi
- Kamal Mohammadian (ORCID: https://orcid.org/0000-0003-4635-7366)
- Maryam Mehrpooya (ORCID: https://orcid.org/0000-0003-4119-1600)
- Reyhaneh Bayani (ORCID: https://orcid.org/0000-0003-0672-810X)
- Mohammad Abbasi (ORCID: https://orcid.org/0000-0002-2964-0357)
- Elyas Hassanzadeh (ORCID: https://orcid.org/0009-0008-9662-9888)
Institutions
- Hamedan University of Medical Sciences (IR)
- University of Tehran (IR)
- Imam Khomeini Hospital (IR)
- Kurdistan University of Medical Sciences (IR)
- Cancer Research Center (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1097/coc.0000000000001153
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.85